Barclays Forecasts Strong Price Appreciation for DaVita (NYSE:DVA) Stock

DaVita (NYSE:DVA) had its target price raised by Barclays from $150.00 to $164.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other research analysts have also recently issued reports about the company. Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. UBS Group raised their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. TD Cowen raised their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Trading Down 1.0 %

Shares of NYSE:DVA opened at $139.81 on Thursday. The company has a market cap of $11.46 billion, a P/E ratio of 15.08, a PEG ratio of 0.82 and a beta of 0.87. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.12. DaVita has a 1 year low of $76.17 and a 1 year high of $168.50. The stock’s fifty day moving average price is $157.96 and its 200-day moving average price is $145.97.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.85 earnings per share. Sell-side analysts expect that DaVita will post 9.84 earnings per share for the current year.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the sale, the chief operating officer now owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock valued at $27,387,069 over the last quarter. 2.00% of the stock is currently owned by company insiders.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Holdings Inc. increased its stake in DaVita by 1.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company’s stock worth $18,612,000 after acquiring an additional 2,129 shares during the last quarter. First Trust Direct Indexing L.P. boosted its holdings in shares of DaVita by 3.9% in the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after purchasing an additional 98 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of DaVita by 175.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company’s stock worth $2,614,000 after purchasing an additional 12,064 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in shares of DaVita in the 1st quarter worth approximately $2,899,000. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of DaVita by 11.9% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,377 shares of the company’s stock worth $328,000 after purchasing an additional 253 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.